Xcout IntelAadi Bioscience, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Aadi Bioscience, Inc. among biotechnology companies — ranked by similarity to what Aadi Bioscience, Inc. actually does, not by market-cap band.
Subscribe to see Aadi Bioscience, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company headquartered in Morristown, New Jersey, focused on developing precision therapies for genetically defined cancers.
Aadi Bioscience, Inc. at a glance
Aadi Bioscience, Inc. is a biotechnology company headquartered in United States. It has raised at least $373.5M across the 5 funding rounds on record. Its most recent funding round raised $100M in March 2025. Xcout tracks 13 named people at Aadi Bioscience, Inc., including Bryan Ball (Executive Officer).
Aadi Bioscience, Inc. leadership
- Bryan BallExecutive Officer
- Dave LennonExecutive Officer
- David DornanExecutive Officer
- Scott GiacobelloExecutive Officer
- Anupam DalalDirector
- Baiteng ZhaoDirector
7 more named people on record for Aadi Bioscience, Inc., with roles, board committees and tenure — see the full roster →
Aadi Bioscience, Inc. funding rounds
At least $373.5M raised across the 5 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $100M | — | |
| SEC Form D filing | $72.5M | — | |
| SEC Form D filing | $155M | — | |
| Series A | $23M | 1 named | |
| Series A | $23M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Aadi Bioscience, Inc. competitors
Ranked by semantic similarity — how close each company is to Aadi Bioscience, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Similar biotechnology company
Edison Oncology Holding Corp is a clinical-stage biopharmaceutical company that develops first-in-class, small-molecule, biomarker-driven therapies to target major cancer markets. The company identifies, acquires, and advances underdeveloped drug candidates to address critical unmet needs for cancer patients with specific genetic mutations.
Similar biotechnology company
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Similar biotechnology company
Affini-T Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, specializing in the development of precision immunotherapies and T-cell therapies for cancer patients.
Biotech
Blueprint Medicines Corporation is a global precision therapy company that invents life-changing medicines, operating as a Sanofi company.
Biotech
Mirador Therapeutics, Inc. is a clinical-stage precision medicine company headquartered in San Diego, California, focused on developing first- and best-in-class next-generation therapeutics.
Biotech
AUM Biosciences is a clinical-stage biotechnology company that develops precision oncology therapeutics utilizing multi-faceted inhibition strategies to overcome cancer drug resistance. The company serves patients and the healthcare sector by advancing a targeted clinical pipeline designed to combat tumor evasion and treatment resistance.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Similar biotechnology company
Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.
Biotech
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Biotech
Aptose Biosciences Inc. is a clinical-stage biotechnology company that develops small molecule cancer therapeutics, focusing on precision medicines for hematologic malignancies. The company's product pipeline features investigational drug candidates such as tuspetinib and luxeptinib, which are designed to treat conditions like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and B-cell malignancies.
Biotech
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Aadi Bioscience, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Aadi Bioscience, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →